Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients

scientific article

Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1191/0961203304LU1080OA
P8608Fatcat IDrelease_xj2n5tsnb5dezleztpujtpixky
P698PubMed publication ID15540510

P50authorJosep FontQ73474655
Miguel IngelmoQ73600642
Manuel Ramos-casalsQ42646201
Sonia SeguraQ42882490
Ricard Cervera i SeguraQ53547424
Antonio-J ChamorroQ56956958
P2093author name stringJ Yagüe
M T Campoamor
G Salvador
J C Botero
P2860cites workComplement. First of two partsQ28210663
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosusQ29614922
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus ErythematosusQ33329033
Complement C3 activation is required for antiphospholipid antibody-induced fetal lossQ33340713
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patientsQ33341941
Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosusQ33556592
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshopQ33685960
Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnanciesQ34131724
Update on complement in the pathogenesis of systemic lupus erythematosusQ34793539
Cardiac valvulopathy in the antiphospholipid syndromeQ34981341
Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decadesQ35551526
Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective studyQ41192552
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosusQ43772908
Immunologic factors and clinical activity in systemic lupus erythematosusQ47817323
Cryoglobulinemia in systemic lupus erythematosus: Prevalence and clinical characteristics in a series of 122 patientsQ56907681
CryoglobulinemiaQ56907690
Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests failQ58161488
P433issue10
P921main subjectsystemic lupus erythematosusQ1485
antiphospholipid syndromeQ582207
primary antiphospholipid syndromeQ63878006
P304page(s)777-783
P577publication date2004-01-01
P1433published inLupusQ6704846
P1476titleHypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients
P478volume13

Reverse relations

cites work (P2860)
Q37318783Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome
Q48159962Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus
Q52852275Atherosclerosis in primary antiphospholipid syndrome.
Q99583920Autoimmunity as the comet tail of COVID-19 pandemic
Q40355684BF*F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus
Q33398064BioPlex 2200 multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus
Q38657043Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers
Q34790651Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions
Q37638376Complement activation and pregnancy failure
Q38109340Complement inhibition in cancer therapy
Q33667257Complete complement deficiency in a large cohort of familial systemic lupus erythematosus
Q38139836Differential diagnosis of glomerular disease: a systematic and inclusive approach
Q39900855Digital vasculitis in systemic lupus erythematosus: a minor manifestation of disease activity?
Q39586997Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome
Q28301662Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody
Q61453809Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus
Q33428578Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss
Q44220435Lupus erythematosus. Wide range of symptoms through clinical variation, associated diseases and imitators
Q28196178Management of the antiphospholipid syndrome
Q64248332Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL)
Q36479278Progress and Trends in Complement Therapeutics
Q84355517Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population
Q36813467T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis
Q44645053Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation.

Search more.